Shu Y - Search Results

1

Clinical perspective of afatinib in non-small cell lung cancer.

Chen X, Zhu Q, Zhu L, Pei D, Liu Y, Yin Y, Schuler M, Shu Y. Chen X, et al. Among authors: shu y. Lung Cancer. 2013 Aug;81(2):155-61. doi: 10.1016/j.lungcan.2013.02.021. Epub 2013 May 10. Lung Cancer. 2013. PMID: 23664448 Review.

2

JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells.

Yin Y, Wang S, Sun Y, Matt Y, Colburn NH, Shu Y, Han X. Yin Y, et al. Among authors: shu y. Biomed Pharmacother. 2009 Jul;63(6):429-35. doi: 10.1016/j.biopha.2009.04.045. Epub 2009 Jun 9. Biomed Pharmacother. 2009. PMID: 19553068 Free PMC article.

3

Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells.

Yin Y, Chen X, Shu Y. Yin Y, et al. Among authors: shu y. Biomed Pharmacother. 2009 Jul;63(6):421-8. doi: 10.1016/j.biopha.2009.04.032. Epub 2009 Jun 13. Biomed Pharmacother. 2009. PMID: 19564093

4

CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients.

Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Liu L, Ge Y, Johnson DE, Ju S, Shu Y. Ju S, et al. Among authors: shu y. Cell Cycle. 2009 Aug 15;8(16):2578-85. doi: 10.4161/cc.8.16.9302. Epub 2009 Aug 19. Cell Cycle. 2009. PMID: 19597336

5

Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.

Shen H, Yuan Y, Sun J, Gao W, Shu YQ. Shen H, et al. Among authors: shu yq. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23. Biomed Pharmacother. 2010. PMID: 20005069

6

A 3'-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population.

Zhang M, Hu Z, Huang J, Shu Y, Dai J, Jin G, Tang R, Dong J, Chen Y, Xu L, Huang X, Shen H. Zhang M, et al. Among authors: shu y. Clin Cancer Res. 2010 Feb 15;16(4):1236-44. doi: 10.1158/1078-0432.CCR-09-2719. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145156

7

miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines.

Zhu W, Shan X, Wang T, Shu Y, Liu P. Zhu W, et al. Among authors: shu y. Int J Cancer. 2010 Dec 1;127(11):2520-9. doi: 10.1002/ijc.25260. Int J Cancer. 2010. PMID: 20162574

8

Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication.

Zhou JN, Huang XE, Ye Z, Li C, Zhang Q, Lin Y, Jiang W, Sunh WL, Shi MQ, Shu YQ. Zhou JN, et al. Among authors: shu yq. Asian Pac J Cancer Prev. 2009;10(6):1147-50. Asian Pac J Cancer Prev. 2009. PMID: 20192601 Free article.

9

Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H. Hu Z, et al. Among authors: shu y. J Clin Oncol. 2010 Apr 1;28(10):1721-6. doi: 10.1200/JCO.2009.24.9342. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194856

10

Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.

Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y. Gao W, et al. Among authors: shu y. Biomed Pharmacother. 2010 Jul;64(6):399-408. doi: 10.1016/j.biopha.2010.01.018. Epub 2010 Feb 25. Biomed Pharmacother. 2010. PMID: 20363096

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,857 results

Search Page

Filters